malignant tumor of digestive tract
Conditions
Interventions
Index test:SUVmax, %ID, TlAC, residence time
Sponsors
Affiliated Hospital of North Sichuan Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Participants who meet all of the following criteria are eligible for admission to this study: 1. A signed informed consent must be obtained before participating in the study. 2. Male or female patients =18 years old. 3. Histologically or cytologically confirmed digestive tumors (including but not limited to gastric, pancreatic, gallbladder, cholangiocarcinoma, hepatocellular carcinoma, colorectal cancer). 4. At least one lymph node, soft tissue, or visceral site metastasis has been confirmed or suspected. 5. ECOG score is 0-2. 6. Adequate organ function: bone marrow reserve: neutrophil count (ANC) = 1.5×10^9/L, platelet count =100×10^9/L, hemoglobin = 90g/L; Liver: total bilirubin (TBIL) =1.5 times the upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 3.0×ULN; Kidney: Serum creatinine (SCr) =1.5×ULN.
Exclusion criteria
Exclusion criteria: Subjects who meet any of the following exclusion criteria will not be admitted to the study: 1. Previously received radioligand therapy. 2. Female subjects who are pregnant or breastfeeding. 3. Are participating in any other clinical trial or have participated in a clinical trial within 28 days of receiving an investigational drug. 4. Patients with central nervous system (CNS) metastases with symptoms or receiving glucocorticoid therapy to maintain the functional integrity of the nervous system. 5. Patients with other malignancies that may interfere with disease assessment, who have prior secondary malignancies that have been adequately treated, who have not received treatment for more than 3 years prior to enrollment, and who have no evidence of recurrence, are eligible to participate in the study. A combination of serious or poorly controlled medical conditions, including but not limited to an infection that is difficult to control, known active hepatitis B or C, or other conditions that the investigator believes may impair study participation or collaboration. 7. Physical or psychiatric history that may interfere with the purpose and evaluation of the study, or any condition in which the investigator determines that the patient is unable to cooperate with the imaging examination and procedure. 8. Patients who do not consent to the use of effective contraception or restrictive practices. 9. There are other conditions that the investigator deems unsuitable for participation in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Biodistribution analysis; | — |
Secondary
| Measure | Time frame |
|---|---|
| Radioactive absorbed dose analysis; | — |
Countries
China
Contacts
Public ContactShiyu Lin
Affiliated Hospital of North Sichuan Medical College
Outcome results
None listed